mechlorethamine has been researched along with Dermatitis, Contact in 35 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
Dermatitis, Contact: A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two groups of 20 patients with psoriasis were treated with mechlorethamine applied topically (group A) or with PUVA combined with mechlorethamine (group B)." | 9.05 | PUVA therapy prevents sensitization to mechlorethamine in patients with psoriasis. ( Mauduit, G; Silvestre, O; Thivolet, J, 1985) |
| "The feasibility of employing adjuvant topical mechlorethamine after electron beam therapy in the treatment of patients with mycosis fungoides is demonstrated." | 9.04 | The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy. ( Constantine, VS; Farber, EM; Fuks, ZY; Hoppe, RT; Price, NM, 1977) |
| "The treatment of skin disease with topical mechlorethamine has been restricted because of the frequent development of contact dermatitis." | 7.66 | Ointment-based mechlorethamine treatment for mycosis fungoides. ( Deneau, DG; Hoppe, RT; Price, NM, 1983) |
| "The use of topical mechlorethamine hydrochloride in the treatment of skin disease has been restricted because of the frequent development of contact dermatitis." | 7.66 | The treatment of mycosis fungoides with ointment-based mechlorethamine. ( Deneau, DG; Hoppe, RT; Price, NM, 1982) |
| "The topical application of mechlorethamine is associated with a high incidence of irritant contact dermatitis." | 7.66 | Topical mechlorethamine for psoriasis. An attempt to avoid the development of sensitization by the use of a topical tolerogenic schedule. ( Price, NM, 1979) |
| "Patients with limited skin involvement by mycosis fungoides were treated with daily topical mechlorethamine." | 7.65 | Topical mechlorethamine therapy for mycosis fungoides. ( Constantine, VS; Farber, EM; Fuks, ZY; Hoppe, RT; Price, NM, 1977) |
| "Six patients with mycosis fungoides were treated with topical mechlorethamine hydrochloride for periods of two to four years." | 7.65 | Topical mechlorethamine. Cutaneous changes in patients with mycosis fungoides after its administration. ( Price, NM, 1977) |
| "Eight patients with psoriasis who had developed contact allergy to mechlorethamine hydrochloride (nitrogen mustard) were subjected to a regimen of intravenous infusion of small amounts of the drug in an attempt to produce desensitization." | 7.65 | Intravenous desensitization to mechlorethamine in patients with psoriasis. ( Childers, RC; Halprin, KM; Kechijian, P; Pariser, DM; Taylor, JR, 1976) |
| "Five patients with mycosis fungoides who had developed contact dermatitis to a nitrogen mustard, mechlorethamine hydrochloride, even in low concentrations (1 to 5 mg/100 ml), received daily total-body applications of extremely dilute solutions (0." | 7.65 | Mechlorethamine desensitization in therapy for mycosis fungoides. Topical desensitization to mechlorethamine (nitrogen mustard) contact hypersensitivity. ( Constantine, VS; Farber, EM; Fuks, ZY, 1975) |
| "Contact dermatitis from phenoxybenzamine hydrochloride occurred in a woman laboratory technician." | 7.65 | Allergic contact dermatitis from phenoxybenzamine hydrochloride: cross-sensitivity to some related haloalkylamine compounds. ( Maibach, HI; Mitchell, JC, 1975) |
| " Six of these patients showed allergic contact dermatitis to mechlorethamine after a mean period of 9." | 5.10 | Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment. ( Dalac, S; Delaunay, M; Dréno, B; Evrard, V; Foulc, P; Guillot, B; Verret, JL, 2002) |
| "Two groups of 20 patients with psoriasis were treated with mechlorethamine applied topically (group A) or with PUVA combined with mechlorethamine (group B)." | 5.05 | PUVA therapy prevents sensitization to mechlorethamine in patients with psoriasis. ( Mauduit, G; Silvestre, O; Thivolet, J, 1985) |
| "The feasibility of employing adjuvant topical mechlorethamine after electron beam therapy in the treatment of patients with mycosis fungoides is demonstrated." | 5.04 | The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy. ( Constantine, VS; Farber, EM; Fuks, ZY; Hoppe, RT; Price, NM, 1977) |
| "The treatment of skin disease with topical mechlorethamine has been restricted because of the frequent development of contact dermatitis." | 3.66 | Ointment-based mechlorethamine treatment for mycosis fungoides. ( Deneau, DG; Hoppe, RT; Price, NM, 1983) |
| "The use of topical mechlorethamine hydrochloride in the treatment of skin disease has been restricted because of the frequent development of contact dermatitis." | 3.66 | The treatment of mycosis fungoides with ointment-based mechlorethamine. ( Deneau, DG; Hoppe, RT; Price, NM, 1982) |
| "The topical application of mechlorethamine is associated with a high incidence of irritant contact dermatitis." | 3.66 | Topical mechlorethamine for psoriasis. An attempt to avoid the development of sensitization by the use of a topical tolerogenic schedule. ( Price, NM, 1979) |
| "Patients with limited skin involvement by mycosis fungoides were treated with daily topical mechlorethamine." | 3.65 | Topical mechlorethamine therapy for mycosis fungoides. ( Constantine, VS; Farber, EM; Fuks, ZY; Hoppe, RT; Price, NM, 1977) |
| "Six patients with mycosis fungoides were treated with topical mechlorethamine hydrochloride for periods of two to four years." | 3.65 | Topical mechlorethamine. Cutaneous changes in patients with mycosis fungoides after its administration. ( Price, NM, 1977) |
| "Eight patients with psoriasis who had developed contact allergy to mechlorethamine hydrochloride (nitrogen mustard) were subjected to a regimen of intravenous infusion of small amounts of the drug in an attempt to produce desensitization." | 3.65 | Intravenous desensitization to mechlorethamine in patients with psoriasis. ( Childers, RC; Halprin, KM; Kechijian, P; Pariser, DM; Taylor, JR, 1976) |
| "Five patients with mycosis fungoides who had developed contact dermatitis to a nitrogen mustard, mechlorethamine hydrochloride, even in low concentrations (1 to 5 mg/100 ml), received daily total-body applications of extremely dilute solutions (0." | 3.65 | Mechlorethamine desensitization in therapy for mycosis fungoides. Topical desensitization to mechlorethamine (nitrogen mustard) contact hypersensitivity. ( Constantine, VS; Farber, EM; Fuks, ZY, 1975) |
| "Contact dermatitis from phenoxybenzamine hydrochloride occurred in a woman laboratory technician." | 3.65 | Allergic contact dermatitis from phenoxybenzamine hydrochloride: cross-sensitivity to some related haloalkylamine compounds. ( Maibach, HI; Mitchell, JC, 1975) |
| " However, the optimal regimen regarding frequency and dosing as well as combination and maintenance therapy is not well established." | 2.82 | The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region). ( Assaf, C; Booken, N; Dippel, E; Guenova, E; Jonak, C; Klemke, CD; Nicolay, JP; Schlaak, M; Trautinger, F; Wobser, M, 2022) |
| "Chlormethine gel was approved for treatment of mycosis fungoides, the most common cutaneous T-cell lymphoma, on the basis of results from study 201 and study 202." | 1.72 | Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data. ( Assaf, C; Guitart, J; Hodak, E; Kim, YH; Quaglino, P; Querfeld, C; Scarisbrick, JJ, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (74.29) | 18.7374 |
| 1990's | 2 (5.71) | 18.2507 |
| 2000's | 1 (2.86) | 29.6817 |
| 2010's | 2 (5.71) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Assaf, C | 2 |
| Booken, N | 1 |
| Dippel, E | 1 |
| Guenova, E | 1 |
| Jonak, C | 1 |
| Klemke, CD | 1 |
| Nicolay, JP | 1 |
| Schlaak, M | 1 |
| Wobser, M | 1 |
| Trautinger, F | 1 |
| Querfeld, C | 1 |
| Scarisbrick, JJ | 1 |
| Kim, YH | 1 |
| Guitart, J | 1 |
| Quaglino, P | 1 |
| Hodak, E | 2 |
| Dong, X | 1 |
| He, Y | 1 |
| Ye, F | 1 |
| Zhao, Y | 1 |
| Cheng, J | 1 |
| Xiao, J | 1 |
| Yu, W | 1 |
| Zhao, J | 1 |
| Sai, Y | 1 |
| Dan, G | 1 |
| Chen, M | 1 |
| Zou, Z | 1 |
| Prag Naveh, H | 1 |
| Amitay-Laish, I | 1 |
| Zidan, O | 1 |
| Leshem, YA | 1 |
| Sherman, S | 1 |
| Noyman, Y | 1 |
| Taieb, J | 1 |
| Didkovsky, E | 1 |
| Inturi, S | 2 |
| Tewari-Singh, N | 2 |
| Jain, AK | 2 |
| Roy, S | 1 |
| White, CW | 2 |
| Agarwal, R | 2 |
| Orlicky, DJ | 1 |
| Foulc, P | 1 |
| Evrard, V | 1 |
| Dalac, S | 1 |
| Guillot, B | 1 |
| Delaunay, M | 1 |
| Verret, JL | 1 |
| Dréno, B | 1 |
| Migdał, A | 1 |
| Kałuzynski, H | 1 |
| LEDER, M | 1 |
| Waldorf, DS | 1 |
| Haynes, HA | 1 |
| Van Scott, EJ | 1 |
| Shelley, WB | 1 |
| Nusbaum, BP | 1 |
| Edwards, EK | 1 |
| Horwitz, SN | 1 |
| Frost, P | 1 |
| Vonderheid, EC | 1 |
| Price, NM | 6 |
| Hoppe, RT | 4 |
| Deneau, DG | 2 |
| Vega, FA | 1 |
| Halprin, KM | 3 |
| Taylor, JR | 5 |
| Woodyard, C | 1 |
| Comerford, M | 2 |
| Presser, SE | 1 |
| Constantine, VS | 3 |
| Fuks, ZY | 3 |
| Farber, EM | 3 |
| Volden, G | 1 |
| Eeg Larsen, T | 1 |
| du Vivier, A | 1 |
| Vollum, D | 1 |
| Leshaw, S | 1 |
| Simon, RS | 1 |
| Bear, RL | 1 |
| Pariser, DM | 1 |
| Childers, RC | 1 |
| Kechijian, P | 2 |
| Breza, TS | 1 |
| Thomsen, K | 1 |
| Mikkelsen, HI | 1 |
| Mitchell, JC | 1 |
| Maibach, HI | 1 |
| Goday, JJ | 1 |
| Aguirre, A | 1 |
| Ratón, JA | 1 |
| Díaz-Pérez, JL | 1 |
| Mauduit, G | 2 |
| Silvestre, O | 1 |
| Thivolet, J | 2 |
| Salle, G | 1 |
| Schott, AM | 1 |
| Parish, WE | 1 |
| Mandy, S | 1 |
| Halprin, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response[NCT00535470] | Phase 2 | 100 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF)[NCT00168064] | Phase 2 | 260 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessment of lesion distribution and severity. A responder analysis was performed on whether subject achieved at least 50% improvement on scale. This had to be confirmed on at least one visit at least 4 weeks apart. (NCT00168064)
Timeframe: Baseline to end of therapy
| Intervention | Percent of participants (Number) |
|---|---|
| PG -Mechlorethamine-MCH (Nitrogen Mustard) 0.02% PG Gel | 61 |
| AP- Mechlorethamine-MCH (NM) 0.02% Compounded in Aquaphor | 60 |
The ratio of the response rate of the patients treated with the PG formulation to the response rate of the patients treated with the AP formulation. Skin response determined by at least a 50% reduction from baseline in the Composite Assessment of Index Lesion Severity (CAILS) following up to 12 months of treatment (NCT00168064)
Timeframe: Assessment made at Day 1 and every subsequent visit during treatment
| Intervention | percentage of participants (Number) |
|---|---|
| PG- Mechlorethamine-MCH (Nitrogen Mustard) 0.02% Gel | 76 |
| AP- Aquaphor Formulation Mechlorethamine-MCH (NM) 0.02% | 62 |
2 reviews available for mechlorethamine and Dermatitis, Contact
| Article | Year |
|---|---|
The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region).
Topics: Austria; Cyclohexylamines; Dermatitis, Contact; Humans; Mechlorethamine; Mycosis Fungoides; Skin Neo | 2022 |
Topical mechlorethamine chemotherapy. Considerations on its use in mycosis fungoides.
Topics: Administration, Topical; Dermatitis, Contact; Humans; Mechlorethamine; Mycosis Fungoides; Skin Neopl | 1984 |
5 trials available for mechlorethamine and Dermatitis, Contact
| Article | Year |
|---|---|
Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dermatit | 2002 |
Psoriasis therapy. The effect of UV radiation on sensitization to mechlorethamine.
Topics: Administration, Topical; Aged; Clinical Trials as Topic; Dermatitis, Contact; Drug Hypersensitivity; | 1983 |
The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy.
Topics: Administration, Topical; Dermatitis, Contact; Female; Humans; Male; Mechlorethamine; Middle Aged; My | 1977 |
PUVA therapy prevents sensitization to mechlorethamine in patients with psoriasis.
Topics: Adult; Aged; Dermatitis, Atopic; Dermatitis, Contact; Drug Eruptions; Drug Therapy, Combination; Fem | 1985 |
Treatment of patients with psoriasis by PUVA therapy and mechlorethamine.
Topics: Dermatitis, Contact; Drug Therapy, Combination; Humans; Mechlorethamine; Psoriasis; PUVA Therapy | 1986 |
28 other studies available for mechlorethamine and Dermatitis, Contact
| Article | Year |
|---|---|
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.
Topics: Clinical Trials as Topic; Dermatitis, Contact; Gels; Humans; Mechlorethamine; Mycosis Fungoides; Oin | 2022 |
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.
Topics: Clinical Trials as Topic; Dermatitis, Contact; Gels; Humans; Mechlorethamine; Mycosis Fungoides; Oin | 2022 |
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.
Topics: Clinical Trials as Topic; Dermatitis, Contact; Gels; Humans; Mechlorethamine; Mycosis Fungoides; Oin | 2022 |
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.
Topics: Clinical Trials as Topic; Dermatitis, Contact; Gels; Humans; Mechlorethamine; Mycosis Fungoides; Oin | 2022 |
Vitamin D3 ameliorates nitrogen mustard-induced cutaneous inflammation by inactivating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway.
Topics: Animals; Dermatitis, Contact; Female; HaCaT Cells; Humans; Inflammasomes; Keratinocytes; Mechloretha | 2021 |
Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects
Topics: Adult; Dermatitis, Contact; Dermatologic Agents; Drug-Related Side Effects and Adverse Reactions; Hu | 2022 |
Absence of a p53 allele delays nitrogen mustard-induced early apoptosis and inflammation of murine skin.
Topics: Alkylating Agents; Alleles; Animals; Apoptosis; Dermatitis, Contact; Mechlorethamine; Mice; Mice, Ha | 2013 |
Histopathological and immunohistochemical evaluation of nitrogen mustard-induced cutaneous effects in SKH-1 hairless and C57BL/6 mice.
Topics: Animals; Apoptosis; Blister; Cell Proliferation; Chemical Warfare Agents; Dermatitis, Contact; Disea | 2014 |
[Attempts to treat allergic skin diseases by nitrogranulogen].
Topics: Dermatitis; Dermatitis, Atopic; Dermatitis, Contact; Humans; Hypersensitivity; Mechlorethamine; Nitr | 1952 |
[Occupational skin diseases caused by nitrogen mustard].
Topics: Dermatitis; Dermatitis, Contact; Mechlorethamine; Nitrogen Mustard Compounds; Skin; Skin Diseases | 1952 |
Cutaneous hypersensitivity and desensitization to mechlorethamine in patients with mycosis fungoides lymphoma.
Topics: Cyclophosphamide; Dermatitis, Contact; Desensitization, Immunologic; Dosage Forms; Drug Hypersensiti | 1967 |
Focal contact sensitivity to nitrogen mustard in lesions of cutaneous T-cell lymphoma (mycosis fungoides).
Topics: Administration, Topical; Dermatitis, Contact; Humans; Male; Mechlorethamine; Middle Aged; Mycosis Fu | 1981 |
Ointment-based mechlorethamine treatment for mycosis fungoides.
Topics: Administration, Topical; Dermatitis, Contact; Evaluation Studies as Topic; Humans; Mechlorethamine; | 1983 |
The treatment of mycosis fungoides with ointment-based mechlorethamine.
Topics: Administration, Topical; Dermatitis, Contact; Humans; Mechlorethamine; Mycosis Fungoides; Ointment B | 1982 |
Failure of periodic ultraviolet radiation treatments to prevent sensitization to nitrogen mustard: a case report.
Topics: Cell Count; Dermatitis, Contact; Humans; Langerhans Cells; Male; Mechlorethamine; Middle Aged; Mycos | 1982 |
Ultraviolet light treatment delays contact sensitization to nitrogen mustard.
Topics: Adult; Aged; Dermatitis, Contact; Female; Humans; Male; Mechlorethamine; Middle Aged; Psoriasis; PUV | 1981 |
[Can cutaneous intolerance reactions to caryolysine be prevented or controlled?].
Topics: Administration, Topical; Antineoplastic Agents, Alkylating; Dermatitis, Contact; Humans; Lymphoproli | 1997 |
Topical mechlorethamine for psoriasis. An attempt to avoid the development of sensitization by the use of a topical tolerogenic schedule.
Topics: Administration, Topical; Dermatitis, Contact; Drug Tolerance; Humans; Mechlorethamine; Psoriasis | 1979 |
Topical mechlorethamine therapy for mycosis fungoides.
Topics: Administration, Topical; Dermatitis, Contact; Desensitization, Immunologic; Female; Humans; Male; Me | 1977 |
[Mycosis fungoides].
Topics: Administration, Topical; Adult; Aged; Dermatitis, Contact; Humans; Mechlorethamine; Middle Aged; Myc | 1977 |
Mycosis fungoides treated by PUVA and mustine hydrochloride.
Topics: Dermatitis, Contact; Female; Furocoumarins; Humans; Mechlorethamine; Mycosis Fungoides; Photochemoth | 1978 |
Topical mechlorethamine. Cutaneous changes in patients with mycosis fungoides after its administration.
Topics: Administration, Topical; Biopsy; Dermatitis, Contact; DNA; Humans; Mechlorethamine; Mycosis Fungoide | 1977 |
Failure to induce tolerance to mechlorethamine hydrochloride.
Topics: Dermatitis, Contact; Dinitrochlorobenzene; Humans; Immune Tolerance; Mechlorethamine; Mycosis Fungoi | 1977 |
Intravenous desensitization to mechlorethamine in patients with psoriasis.
Topics: Administration, Topical; Dermatitis, Contact; Desensitization, Immunologic; Drug Hypersensitivity; H | 1976 |
Mechlorethamine desensitization in therapy for mycosis fungoides. Topical desensitization to mechlorethamine (nitrogen mustard) contact hypersensitivity.
Topics: Administration, Topical; Aged; Dermatitis, Contact; Desensitization, Immunologic; Humans; Male; Mech | 1975 |
Mechlorethamine in psoriasis. Further attempts to induce immunological tolerance.
Topics: Adult; Dermatitis, Contact; Humans; Hypersensitivity; Immune Tolerance; Male; Mechlorethamine; Psori | 1975 |
Protective capacity of gloves used for handling of nitrogen mustard.
Topics: Dermatitis, Contact; Female; Humans; Mechlorethamine; Polyvinyl Chloride; Protective Clothing; Rubbe | 1975 |
Allergic contact dermatitis from phenoxybenzamine hydrochloride: cross-sensitivity to some related haloalkylamine compounds.
Topics: Adult; Animals; Dermatitis, Contact; Ethylamines; Female; Guinea Pigs; Humans; Mechlorethamine; Patc | 1975 |
Local bullous reaction to topical mechlorethamine (mustine).
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Dermatitis, Contact; Drug Eruptions; Humans; Mal | 1990 |
Effects of neutrophils on tissues. Experiments on the Arthus reaction, the flare phenomenon, and post-phagocytic release of lysosomal enzymes.
Topics: Animals; Arthus Reaction; Dermatitis, Contact; Guinea Pigs; In Vitro Techniques; Leukocyte Count; Ly | 1969 |
Topically applied mechlorethamine in the treatment of psoriasis.
Topics: Dermatitis, Contact; Humans; Hydrochloric Acid; Male; Mechlorethamine; Psoriasis; Solutions | 1971 |